Literatur
- 1
Ballantyne C, Houri J, Notarbartolo A, Melani L, Lipka L J, Suresh R, Sun S, LeBeaut A,
Sager P T, Veltri E P.
Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary
Hypercholesterolemia- A prospective, Randomized, Double Blind Trial.
Circulation.
2003;
107
2409-2415
- 2
Collins R, Armitage J, Parish S, Sleigh P, Peto R.
Heart Protection Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering
with simvastatin in 5963 people with diabetes: a randomised placebo-controlled
trial.
Lancet.
2003;
361
2005-2016
- 3
Evans M, Robert A, Davies S, Rees A.
Medical lipid lowering therapy: current evidence, ongoing trails and future
developments.
Drugs.
2004;
64
1181-1196
- 4
Farnier M.
Ezetimib in hypercholesterolaemia.
Int J Clin Pract.
2002;
56
611-614
- 5
Gagné C, Gaudet D, Bruckert E. for the Ezetimibe Study Group .
Efficiency and Safety of Ezetimibe Coadministration With Atorvastatin or Simvastatin
in Patients With Homozygous Familial Hypercholesterolemia.
Circulation.
2002;
105
2469-2475
- 6
Goldberg A C, Sapre A, Lui J, Capece R, Mitchel Y B. Ezetimibe Study Group .
Efficiency and safety of Ezetimibe coadministered with Simvastatin in patients
with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled
trial.
Mayo Clin Proc.
2004;
79
620-629
- 7
Kerzner B, Corbelli J, Sharps S, Lipka L J, Malani L, LeBeaut A, Suresh R, Mukhopadhyay P,
Veltri E P. Ezetimibe Study group .
Efficacy and safety of Ezetimibe coadministration with Lovastatin in primary
hypercholesterolemia.
Am J Cardiol.
2003;
91
418-424
- 8
Kosoglou T, Meyer I, Veltri E P, Statkevich P, Yang B, Mellars L, Maxwell S E, Patrick J E,
Cutler D L, Batra V K, Affrime M B.
Pharmacodynamic interactions between the new selective cholesterol absorption
inhibitor Ezetimibe and Simvastatin.
J Clin Pharmacol.
2002;
54
309-319
- 9
Miettinen T.
Cholesterol Absorption Inhibition: A Strategy for Cholesterol-Lowering Therapy.
Int J Clin Pract.
2001;
55
710-716
- 10 Mutschler E, Geisslinger G, Kroemer H K, Schäfer-Korting M. Arzneimittelwirkungen
- Lehrbuch der Pharmakologie und Toxikologie,. 8. völlig neu bearb. und erw.
Auflage Stuttgart: Wiss. Verl.-Ges 2001
- 11
Paternak R C.
Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education
Program guidelines on the detection, evaluation and treatment of elevated cholesterol
in adults.
Cardiol Clin.
2003;
21
393-398
- 12
Pedersen T R, Kjekshus J, Berg K, Olsson A G, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T,
Haghfelt T, Feargeman O, Thorgeirsson G, Jönsson B, Schwartz J S.
Cholesterol Lowering and the Use of Healthcare Resources, Results of the Scandinavian
Simvastatin Survival Study.
Circulation.
1996;
94
849
- 13
Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble D L, Shah S, Perevozskaya I, von Bergmann K.
Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans.
Circulation.
2002;
106
1943-1948
- 14
Voss R, Cullen P, Schulte H, Assmann G.
Prediction of risk of coronary events in middle-aged men in the Prospective
Cardiovascular Münster (PROCAM) using neural networks.
Intern J Epidemiology.
2002;
31
1253-1262
- 15
Watzl B, Rechkemmer G.
Phytosterine, Charakteristik, Vorkommen, Aufnahme, Stoffwechsel, Wirkungen.
Ernährungs-Umschau.
2001;
48/4
- 16
Wierzbicki A S, Lumb P J, Semra Y, Chik G, Christ E R, Crook M A.
Atorvastatin compared with simvastatin-based therapies in the management of
severe familial hyperlipidaemias.
Q J Med.
1999;
92
387-394
Henriette Meyer zu Schwabedissen
Prof. Dr. rer. nat. H. K. Kroemer
Abteilung für Allgemeine Pharmakologie, Institut für Pharmakologie und Toxikologie,
Ernst-Moritz-Arndt Universität Greifswald
Friedrich Löffler Straße 23d
17487 Greifswald
